riluzole and Atrophy
riluzole has been researched along with Atrophy in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging." | 5.10 | The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. ( Barkhof, F; Bergers, E; Kalkers, NF; Polman, CH; van Schijndel, R, 2002) |
| "Fatigue is a common and disabling symptom of multiple sclerosis (MS) patients." | 1.43 | Longitudinal associations between brain structural changes and fatigue in early MS. ( Azevedo, C; Maghzi, AH; Nourbakhsh, B; Nunan-Saah, J; Pelletier, D; Spain, R; Waubant, E, 2016) |
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Nourbakhsh, B | 3 |
| Azevedo, C | 2 |
| Nunan-Saah, J | 1 |
| Maghzi, AH | 2 |
| Spain, R | 2 |
| Pelletier, D | 3 |
| Waubant, E | 3 |
| Kuhle, J | 1 |
| Grant, D | 1 |
| Morant, S | 1 |
| Barro, C | 1 |
| Yaldizli, Ö | 1 |
| Giovannoni, G | 1 |
| Gnanapavan, S | 1 |
| Kalkers, NF | 1 |
| Barkhof, F | 1 |
| Bergers, E | 1 |
| van Schijndel, R | 1 |
| Polman, CH | 1 |
Clinical Trials (3)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis[NCT00501943] | Phase 2 | 43 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple Sclerosis.[NCT04593082] | 116 participants (Anticipated) | Observational | 2021-06-03 | Recruiting | |||
| OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial[NCT02104661] | Phase 2 | 30 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Changes in MS Functional Composite (MSFC)
Baseline MSFC data is compared to MSFC data collected during the timepoints. The MSFC is a three-part, standardized, quantitative, assessment instrument that measures the clinical dimensions of leg function, arm/hand function and cognitive function and the components include Timed 25-Foot walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test. (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | 0.041 |
| Placebo | 0.052 |
Changes in Normalized Grey Matter Volume
The baseline data of grey matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -14.369 |
| Placebo | -18.444 |
Changes in Normalized White Matter Volumes (nWMV)
The baseline data of white matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -1.75 |
| Placebo | -9.69 |
Changes in Peripapillary Retinal Nerve Fiber Layer Thickness (RNFL)
Baseline RNFL data is compared to the RNFL data collected during the timepoint, and the changes in RNFL is measured using optical coherence tomography (OCT). (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -4.670 |
| Placebo | -1.839 |
Changes in Symbol Digit Modality Test (SDMT)
Baseline SDMT data were compared to SDMT data collected during the timepoints. A simple substitution task, the SDMT gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The total score is the total number of correctly completed boxes in the time allowed. The test score range is from 0(worst outcome) to 110 (best outcome). (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | 0.342 |
| Placebo | 0.417 |
MRI Parameter- Percent Brain Volume Change for 2 Years
Baseline MRI is compared to MRI images collected during subsequent timepoints. The percent brain volume change is measured using SIENAX (Structural Image Evaluation using Normalization of Atrophy-X) (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -0.862 |
| Placebo | -0.49 |
Trials
3 trials available for riluzole and Atrophy
| Article | Year |
|---|---|
Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Brain; Cross-Sectional Studies; Disability Evaluation; Disea | 2016 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Topics: Adult; Aged; Atrophy; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclero | 2002 |
Other Studies
1 other study available for riluzole and Atrophy
| Article | Year |
|---|---|
Longitudinal associations between brain structural changes and fatigue in early MS.
Topics: Adult; Atrophy; Brain; Fatigue; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Ma | 2016 |